Movement Alert|Kodiak Sciences Inc. Intraday Rise 5.73% in Regular Trading, gains supported by continued digestion of insider buying and late-stage trial progress

Market Focus10-29

On October 29, Kodiak Sciences Inc. rose 5.73% in Regular Trading, trading at $103.39 per share, with turnover of $16.24 million.

The move coincided with continued market digestion of a large insider purchase by director and major shareholder Felix Baker, alongside previously disclosed positive Phase 3 data for the company’s retinal disease drug candidates.

Background context shows Baker acquired about $157 million of shares in late September through affiliated entities at $80.85 per share, described as his largest purchase to date, further increasing the Baker-related stake. Separately, the company said Zenkuda and tabirafusp-ted met primary endpoints in a Phase 3 wet AMD study, and it plans to submit Zenkuda data from five positive Phase 3 studies to regulators in the fourth quarter, reinforcing expectations for future filings and product potential.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment